Life Science Compliance Update

Press Releases

  • WASHINGTON, August 18, 2015 — Could the Sunshine Act be creating an unintentional downward trend in clinical research? An analysis of the U.S. government’s Open Payments database shows that industry spending on U.S-based clinical research has dropped 32 percent in the first year-over-year comparison since Open Payments data started to be collected. The results are published in the August issue of Life Science Compliance Update, a monthly newsletter published by Policy & Medicine.

  • COLUMBIA, Md., April 14, 2015 — In today’s highly regulated healthcare environment, commercial compliance has become among the most pressing topics on the minds of pharmaceutical and medical device executives. Yet, there is no single publication that goes deep enough to shed light on the myriad issues facing these executives, according to Thomas Sullivan, Editor of Policy & Medicine, the leading daily information resource on life science compliance. “It seems that in every pharma meeting–no matter what topic–half the discussion is focused around compliance,” said Sullivan. “Whether it’s the Sunshine Act or implementing CIAs or the Anti-Kickback Statute or False Claims Act, there’s a lot of talk about what’s important and what companies should be doing to meet standards.”

Menu Title